Dendritic-cell activity
Laboratory studies report effects on dendritic-cell maturation, antigen presentation, and communication with T cells.
P—09 • Internationally established research profile
Thymosin Alpha-1
A concise educational overview of a 28-amino-acid thymic peptide studied for its context-dependent effects on innate and adaptive immune signaling.
Name
Thymosin Alpha-1
Also known as Tα1 or thymalfasin
- Scientific classification
- Naturally occurring N-terminally acetylated 28-amino-acid thymic peptide; thymalfasin is its chemically synthesized form
- Library family
- Immune
- Research status
- Clinically established in certain international markets, with continuing clinical research; unapproved in the United States
- Regulatory status
- Not FDA approved; authorized for specific uses in certain countries, while a 2024 FDA advisory committee voted against adding the free base and acetate forms to the 503A Bulks List
Compound overview
An immune-modulating thymic peptide with international clinical use.
Thymosin Alpha-1 is an immune-modulating peptide originally isolated from a thymic peptide preparation. Its chemically synthesized form is called thymalfasin.
Researchers examine how it influences communication between innate and adaptive immune cells. Its effects are better described as immune modulation than as universally boosting the immune system. It is different from thymosin beta-4 and the TB-500 fragment.
Mechanism under study
Coordinating innate and adaptive immune signaling
Thymosin Alpha-1 has context-dependent effects across several immune-cell pathways. It does not appear to act through one universally established receptor or mechanism.
Toll-like receptor signaling
Preclinical research connects Tα1 with several Toll-like receptor pathways, including TLR9-dependent signaling.
Adaptive responses
Studies examine its influence on T-cell maturation, activation, cytokine signaling, and immune-response coordination.
Certain models also suggest that Tα1 can support regulatory pathways involving IDO, IL-10, and regulatory T cells, illustrating that its effects depend on the immune context.
Current research areas
Questions under investigation
- Immune-cell restoration and regulation
- Chronic viral infections, including hepatitis research
- Sepsis and critical-illness immune dysfunction
- Vaccine-response research
- Oncology and post-treatment immune recovery
Evidence summary
Clinical and immune-modulation findings
- Immune modulation: Laboratory and clinical studies report changes in dendritic-cell activity, T-cell function, cytokines, and selected immune biomarkers.
- International clinical use: Specific Tα1 products are authorized in certain countries for defined hepatitis or vaccine-adjuvant indications. These approvals do not establish effectiveness for unrelated conditions.
- Chronic hepatitis research: Clinical trials have produced mixed findings, and Thymosin Alpha-1 is not recommended as a standard treatment in current U.S. hepatitis B guidelines.
- Sepsis research: Earlier studies suggested possible benefit, but a large double-blind Phase 3 trial involving more than 1,000 adults found no clear reduction in 28-day mortality.
- Other immune-related uses: Evidence for generalized immune enhancement, chronic fatigue, long COVID, Lyme disease, or broad wellness applications is insufficient.
The evidence is most informative when interpreted by disease, formulation, international product, and specific immune context.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, treatment guidance, dosing information, or instructions for Thymosin Alpha-1 use. Regulatory authorization and evidence differ by country, product, formulation, and medical indication. Compounded products are not FDA approved and are not reviewed by the FDA for safety, effectiveness, or manufacturing quality before marketing.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.